Renovorx ceo issues update letter to shareholders

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from chief executive officer, shaun bagai. dear fellow renovorx shareholders, the first quarter of 2024 marked a significant period in our company's evolution, and we have set the stage for significant milestones in the foreseeable.
RNXT Ratings Summary
RNXT Quant Ranking